Tuesday, December 16, 2014
Media and social stigma can influence the patient adaptation to neurotechnologies and DBS
Deep Brain Stimulation (DBS) is one of the oldest neuromodulation techniques; it was approved by the FDA in 1997 for the treatment of <a href="http://www navigate to this web-site.ncbi.nlm.nih.gov/pubmedhealth/PMH0001768/” onclick=”_gaq.push([‘_trackEvent’, ‘outbound-article’, ‘http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001768/’, ‘essential tremor’]);” >essential tremor, and a few years later, in 2002, the indication was extended to the treatment of Parkinson’s disease and dystonia (in 2003). In 2009 a new era for DBS started when the FDA also approved it as a therapy for obsessive-compulsive disorder. Some patients experienced a very good outcome, while others were less lucky and experienced side effects such as cognitive, behavioral or psychosocial impairments. DBS is now a common procedure for the treatment of many motor and behavioral impairments.